Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 15/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529716 | 0.90 | MELK (0.46) | MELK | |
| SCHEMBL529522 | 0.83 | MELK (0.51) | MELKEGFRERBB2 | |
| SCHEMBL529063 | 0.83 | MELK (0.50) | MELKEGFRERBB2 | |
| SCHEMBL5655413 | 0.82 | MELK (0.48) | MELKTAAR1NPC1NCOA1NCOA3 | |
| SCHEMBL529048 | 0.82 | MELK (0.73) | MELK | |
| SCHEMBL530050 | 0.81 | MELK (0.69) | MELK | |
| SCHEMBL529513 | 0.79 | MELK (0.48) | MELK | |
| SCHEMBL528701 | 0.79 | MELK (0.74) | MELK | |
| SCHEMBL529029 | 0.78 | MELK (0.71) | MELK | |
| SCHEMBL529164 | 0.77 | MELK (0.75) | MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |